SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Biopharma Update on the Novel Coronavirus: September 4
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
September 3, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Jana Shea/Shutterstock
Drug Development
Amylyx’ ALS Drug Shows Promise in Phase II/III Clinical Trial
Amylyx Pharmaceuticals published data from its Phase II/III CENTAUR clinical trial evaluating AMX0035 in amyotrophic lateral sclerosis (ALS) which met its primary endpoint.
September 3, 2020
 · 
3 min read
 · 
Mark Terry
Courtesy of Willy Barton/Getty Images
Business
Sanofi, GSK Move COVID-19 Vaccine Candidate Into the Clinic, Expect Data by December
Months after forging a development partnership for a COVID-19 vaccine, GlaxoSmithKline and Sanofi are moving their adjuvanted vaccine candidate into the clinic.
September 3, 2020
 · 
2 min read
 · 
Alex Keown
Business
BioSpace Global Roundup, Sept. 3
Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.
September 2, 2020
 · 
7 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: September 2
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 2, 2020.
September 1, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Vir Bio and GSK Join the Race for a COVID-19 Monoclonal Antibody Therapy
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
August 31, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: August 31
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
August 31, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Clinical Catch-Up: August 24-28
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
August 31, 2020
 · 
5 min read
 · 
Mark Terry
Business
Biopharma Update on the Novel Coronavirus: August 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 28, 2020.
August 28, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Takeda and Ovid’s Epilepsy Drug Sees Positive Results in Phase II Trial
Takeda Pharmaceutical and Ovid Therapeutics announced on Tuesday that they have gathered positive data from their Phase II ELEKTRA study of soticlestat in children with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS).
August 26, 2020
 · 
3 min read
 · 
Krystle Vermes
Load More
PRESS RELEASES
Press Releases
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
January 19, 2026
 · 
3 min read
Press Releases
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
January 16, 2026
 · 
8 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
 · 
7 min read
Press Releases
HMNC Brain Health Presented Positive Phase 2b Data at American College of Neuropsychopharmacology Annual Meeting
January 16, 2026
 · 
3 min read
Press Releases
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
January 16, 2026
 · 
7 min read
Press Releases
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
January 16, 2026
 · 
4 min read
Press Releases
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral ‘XAFTY’ Following 2026 Biotech Showcase Consensus
January 15, 2026
 · 
3 min read
Press Releases
Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology
January 15, 2026
 · 
8 min read
Press Releases
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
January 14, 2026
 · 
4 min read
Press Releases
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
January 14, 2026
 · 
10 min read
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
 · 
4 min read
Press Releases
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
January 13, 2026
 · 
4 min read
Press Releases
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
January 13, 2026
 · 
2 min read
Press Releases
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
January 13, 2026
 · 
3 min read
Press Releases
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
January 13, 2026
 · 
5 min read
Press Releases
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
January 13, 2026
 · 
4 min read
Press Releases
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
January 13, 2026
 · 
4 min read
Press Releases
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
January 13, 2026
 · 
7 min read
Press Releases
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
January 13, 2026
 · 
7 min read
Press Releases
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
January 13, 2026
 · 
9 min read
Load More